Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab

Matsumoto, Toshihiko; Oda, Takashi; Yoshida, Yu; Kimura, Shogo; Himei, Hitomi; Tsuduki, Takao; Takagi, S.; Takatani, Masahiro; Morishita, Hirofumi

doi:10.1007/s13691-019-00396-0

Cited by 6 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four cases of TC are associated with trastuzumab therapy. [30][31][32][33] Trastuzumab is a recombinant humanized monoclonal antibody that binds the human epidermal growth factor 2 (HER2 or ERBB2). 32 Trastuzumab cardiotoxicity is not dose-dependent and is reversible.…”

Section: Discussionmentioning

confidence: 99%

“…[30][31][32][33] Trastuzumab is a recombinant humanized monoclonal antibody that binds the human epidermal growth factor 2 (HER2 or ERBB2). 32 Trastuzumab cardiotoxicity is not dose-dependent and is reversible. 53 Targeted therapy and immunotherapy are 2 recent innovative strategies in cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

“…More recently, other research groups have proposed slightly different criteria. 1,7 Recently, several anticancer agents have been associated with TC including 5-fluorouracil (5-FU), [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] capecitabine, [23][24][25][26] cytarabine, 27 anthracycline, 28,29 trastuzumab, [30][31][32][33] antiangiogenetic agents, [34][35][36][37] small molecules, [38][39][40] immunological therapy, 41 and also monoclonal antibodies, 42,43 such as immune check point inhibitors. [44][45][46][47] The pathogenesis of anticancer agent-induced TC remains unclear, but is mainly ascribed to the emotional stress associated to the underlying disease, paraneoplastic phenomenon, and direct cardiotoxicity.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports

Carbone

Bottino

Russo

et al. 2021

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Many antitumoral drugs have been linked to takotsubo cardiomyopathy, with no clear pathogenetic mechanisms. Data about this condition are lacking in literature. The aim of this metasummary is to summarize the characteristics of patients with antitumoral drug-induced takotsubo cardiomyopathy, described in case reports available in literature. We searched for published case reports in PubMed, Google Scholar, EMBASE, and Scopus from 2009 about stress cardiomyopathy and antiblastic drugs. We selected 41 case reports. All cases underwent chemotherapy/immunotherapy for different types of cancer. The median age was 58 years, and 61% of them were women. The most common comorbidities were hypertension (12.2%) and dyslipidemia (4.9%), but most of the population had no cardiological clinical history. Takotsubo cardiomyopathy is associated to the 5-fluorouracil (36.5%), capecitabine (9.7%), trastuzumab (9.7%), and immune check point inhibitor (9.7%) treatment. The median time of onset was 2 days (1-150). Cardiogenic shock was the first manifestation in 11 patients (26.8%). Left ventricle ejection fraction recovery was showed in 33 patients (89%) with mean ejection fraction 57.7 6 7%, after a median of 30-day (4-300) follow-up. Patients with cancer experienced takotsubo cardiomyopathy within few days from the beginning of therapy, and the most of them normalized the heart function in few weeks. Cardiogenic shock showed high prevalence in this setting of patients. Larger studies are needed to better understand the pathological mechanisms of antiblastic drug-induced stress cardiomyopathy, to find risk factors associated and preventive strategies for limit this type of cardiotoxicities.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports

Carbone

Bottino

Russo

et al. 2021

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…TS is characterized by acute and reversible symptoms (<21 days) related to LV dysfunction, with an initial clinical picture that mimics that of an ACS, i.e., sudden onset of [15] chest pain, dyspnea, palpitations, ECG abnormalities (ST segment elevation, Q waves and T waves with profound inversion and significant QT prolongation), increased troponin and akinesia of the mid-apical segments of the LV with "apical ballooning", in the absence of significant atheromasia or signs of plaque instability on coronary angiography [7,13,16,17].…”

Section: Systematic Reviewmentioning

confidence: 99%

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer

Irelli,

Ceriello,

Patruno

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Pertuzumab and trastuzumab have been shown to improve the outcomes of patients with metastatic breast cancer, with a rate of left ventricular dysfunction of approximately 6%. We report the case of a postmenopausal woman who presented with Takotsubo syndrome during maintenance therapy with pertuzumab and trastuzumab, in association with fulvestrant (an anti-estrogen) and denosumab. After normalization of cardiac function, therapy with pertuzumab and trastuzumab was resumed in the absence of new cardiac toxicity. We report the first clinical case of Takotsubo syndrome during double anti-HER2 blockade in association with an antiestrogen. Furthermore, we show how anti-HER2 therapy can be safely resumed after the detection of Takotsubo syndrome.

show abstract

“…Takotsubo cardiomyopathy (TTC), also known as “stress cardiomyopathy” or “broken heart syndrome,” is a temporary and reversible heart condition characterized by clinical presentation, ECG, cardiac enzymes, and echocardiography mimicking ACS but with normal coronaries, which typically occurs following intense emotional and mental stress [ 1 ], with resultant excessive catecholamine surge being identified as the most plausible mechanism [ 2 ]. However, this condition could sometimes be triggered by a reaction to a drug [ 3 - 5 ] and/or iatrogenic or exogenous catecholamine administration [ 6 ]. Till now, no case has been reported following administration of a vaccine.…”

Section: Introductionmentioning

confidence: 99%

Reverse Takotsubo Cardiomyopathy Following COVISHIELD Vaccination: A Rare Case of an Anaphylactic Reaction

Shah¹,

Kumar²,

Prajapati³

et al. 2023

Cureus

View full text Add to dashboard Cite

This case report describes a 47-year-old female healthcare worker who developed reverse takotsubo cardiomyopathy (TTC) following the administration of the COVISHIELD COVID-19 vaccine. Within minutes of receiving the vaccine, she experienced acute shortness of breath, nausea, and restlessness, along with a significant drop in blood pressure. She was diagnosed with an anaphylactic reaction and promptly treated with adrenaline and fluids. In the intensive cardiac care unit, she exhibited hypotension, had vision loss, and developed pulmonary edema. Further evaluation revealed abnormal ECG findings, elevated troponin levels, and reduced left ventricular ejection fraction (LVEF). Coronary angiography ruled out obstructive coronary artery disease. The patient gradually improved over several days and was discharged with a recovered left ventricular function. This case highlights the occurrence of TTC triggered by anaphylaxis to the COVID-19 vaccine and emphasizes the need for preparedness to manage such emergencies in vaccination centers.

show abstract

Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab

Cited by 6 publications

References 21 publications

Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports

Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer

Reverse Takotsubo Cardiomyopathy Following COVISHIELD Vaccination: A Rare Case of an Anaphylactic Reaction

Contact Info

Product

Resources

About